The pretransplant pulmonary function test plays an important role in the management of noninfectious pulmonary complications after hematopoietic stem cell transplantation (HCT). Although these tests are widely used as standard preoperative assessments in the nontransplant population, common conditions associated with the HCT patient requires that particular attention be given to interpretation of pulmonary function testing (PFT) results, such as comparison of serial pulmonary function tests and evaluation of the diffusion capacity. Although their utility in helping to predict the likelihood of developing post transplant pulmonary complications and mortality is not well established, current data indicate that pretransplant PFTs are important as a reference for the interpretation of post transplant PFTs and for identifying patients at high risk for developing pulmonary complications and/or mortality after HCT. Future studies of pretransplant pulmonary function should consider the advances in HCT, so that pretransplant PFTs will become a useful tool in pretransplant risk assessment and help the transplant oncologist to determine the most appropriate conditioning regimen for a patient with compromised lung function.
Noninfectious pulmonary complications are well-recognized consequences of allogeneic and autologous hematopoietic stem cell transplants (HCT).
1,2 These complications (Table 1) include syndromes suspected to be associated with the conditioning regimen or HCT-related treatment, such as radiation-induced lung injury, [3] [4] [5] [6] drug toxicity, [7] [8] [9] [10] pulmonary veno-occlusive disease (PVOD), [11] [12] [13] engraftment syndrome, [14] [15] [16] [17] transfusion-related lung injury (TRA-LI), 18, 19 idiopathic pneumonia syndrome, [20] [21] [22] [23] [24] and diffuse alveolar hemorrhage, [25] [26] [27] [28] as well as syndromes suspected to be a consequence of alloreactive activity, such as chronic airflow obstruction (AFO), [29] [30] [31] [32] [33] [34] [35] bronchiolitis obliterans syndrome (BOS), 33, [36] [37] [38] and bronchiolitis obliterans organizing pneumonia. [14] [15] [16] [17] 39 Although the predictive value of pretransplant pulmonary function testing (PFT) is somewhat controversial, most HCT institutions perform routine pretransplant lung function assessment as a baseline reference, in anticipation of these potential pulmonary toxicities. Thus, pretransplant clinical PFTs play an essential role in the management of patients at risk for developing these complications. This review will provide an overview of the parameters assessed in PFTs, highlight the potential pitfalls in interpreting these studies, and provide a detailed synopsis of large studies that have assessed pretransplant lung function as a risk factor for developing post transplant noninfectious pulmonary complications.
Pulmonary function studies
There are three important aspects of a PFT to consider when using pulmonary function data. First, it is important that PFTs are performed in a reputable laboratory by a certified technician, following the American Thoracic Society Guidelines, with an ongoing quality control program. 40, 41 This is particularly critical when considering changes in lung function using PFTs obtained from different laboratories at different times, because changes observed on the tests may not be related to true physiologic change, but instead due to differences in laboratory techniques. Second, the quality of the data must be adequate, meeting the technical requirements for spirometry of good quality. 40 For instance, three acceptable tests should be obtained, with the two largest values for the forced vital capacity (FVC) and forced expiratory volume in the first second (FEV 1 ) within 0.2 L of each other. 40 Third, the clinician should be aware that PFT data are generally reported as a percent of predicted normal values, calculated using population-based reference equations that may vary from laboratory to laboratory. For instance, there exists at least eight reference equations for calculating the predicted normal values for FVC and the FEV 1 among Caucasian men and women. 41 Owing to variability between the reference populations used for these formulas, the observed difference between the calculated percent of predicted normal values from PFTs obtained from different laboratories may be attributable to the use of different formulas, and not to a change in pulmonary physiology. Thus, it is always important to compare the actual values as well as the percent of predicted normal data when reviewing PFT results. A particularly important note is the interpretation of the diffusion capacity, which for the HCT patient, should always be corrected for hemoglobin but not lung volume (see below).
Spirometry
Spirometry measures the rate of air exhaled or inhaled by the patient as a function of time, calculated as the rate of volume change over time (l/s). The reported spirometric values are generally obtained from a forced maximal expiratory vital capacity (FEVC) maneuver, which is measured when a patient forcefully expels air after a maximum inspiration (total lung capacity (TLC), Figure 1) , to a point of maximal expiration (residual volume (RV)). The FVC, the FEV 1 of the FVC maneuver, and the FEV 1 / FVC ratio are the most commonly reported spirometric values from these maneuvers (Figure 1 ). Interpretation of these spirometric results begins by differentiating between an obstructive vs a restrictive physiologic pattern. The American Thoracic Society (ATS) defines airflow obstruction as a disproportionate reduction of the FEV 1 to the FVC to below the lower limit of normal, calculated as: lower limit of normal ¼ predicted value À 1.645 Â the standard error of the estimate. 41 However, in most pulmonary laboratories, an FEV 1 /FVC ratio of p0.7 is generally accepted as an indicator of the presence of an obstructive spirometric pattern. 41 Once an obstructive pattern is evident, the severity of the obstruction is graded using the FEV 1 . Although there is a suggested grading system for pulmonary measurements, 41 the criteria may vary from laboratory and laboratory according to the patient population that laboratory serves. For instance, since over 85% of the allogeneic transplant candidates seen at our center have an FEV 1 480% of predicted normal values prior to transplant, smaller changes in the FEV 1 are noted because they may represent significant changes within this population (Table 2) .
If the FEV 1 and the FVC are decreased proportionally, such that the ratio remains in the normal range despite significant reductions of the FEV 1 and FVC, a restrictive physiologic pattern should be suspected and must be confirmed with lung volume measurements (see below). Another often used value is the forced mid-expiratory flow rate (FEF 25-75% ) This measurement represents the average flow rate between 25 and 75% FVC, and is intended to reflect the most effort-independent portion of the curve, which may be the most sensitive to airflow in peripheral airways, the location where diseases of chronic airflow obstruction are thought to begin. 42, 43 Although the FEF 25-75% is frequently used by clinicians, studies of large cohorts of healthy subjects indicate the FEF 25-75% is widely variable, such that its sensitivity for detecting disease is very limited. 44, 45 When a significant reduction in airflow is detected, spirometry may be repeated after inhalation of a shortacting bronchodilator (BD). The ATS defines a significant BD response as an increase in either the FEV 1 or FVC of 12% or more and an increase in either the FEV 1 or FVC by 0.2 L or more from the pre-BD value. 40 Although a significant BD response may help predict response to therapy for other diseases with airflow obstruction such as asthma, the implications of a significant BD response in an HCT patient who has developed rapid airflow decline has not been well studied. We recently found in a small study that patients who develop new onset airflow obstruction after HCT and have a significant BD response tend to experience a slower annualized rate of percent of predicted FEV 1 decline after initiation of therapy (BD nonresponders, n ¼ 8, À16.7%729; BD responders, n ¼ 4, þ 5.7%78.9, P ¼ 0.08), suggesting that patients with a significant BD response may represent a unique subgroup of patients who experiences significant airflow decline after transplant. 46 
Lung volumes
There are three main lung volume parameters to consider for most PFTs. The total amount of gas in the lungs after a full inspiration (TLC, Figure 1 ), the amount of gas remaining after maximal expiration (RV), and the amount of gas inhaled from RV to TLC (vital capacity (VC)). These volumes can be determined by any of three techniques: (1) closed-circuit inert gas dilution calculates volumes from the equilibrated concentration of a known volume and concentration of gas, usually helium; (2) open-circuit nitrogen washout calculates volume based upon expired nitrogen concentrations before and after breathing pure oxygen; and (3) body plethysmography, which uses Boyle's law (P 1 V 1 ¼ P 2 V 2 ) to determine lung volumes from pressure and volume changes during respiration in a sealed box.
Comparable reduction of the FVC and the FEV 1 , with a reduction in TLC, confirms the suspicion for a restrictive process suggested by the proportional decrease of the FEV 1 and FVC mentioned above. In general, the TLC is reduced when a parenchymal (fibrosis) or chest wall (pleural effusion, muscle weakness, scleroderma) abnormality results in a restrictive pulmonary physiology. Parenchymal disorders typically result in reductions of all the lung volumes. In contrast, a chest wall disorder may reduce the TLC but increase the RV and RV/TLC ratio. This may be confused with an obstructive process, which may occur in up to 26% of patients who survive the first year after HCT. 35 In the presence of an obstructive pattern, the RV/TLC ratio may be increased due to air trapping reflected by an increased RV, while maintaining a normal to slightly elevated TLC. In assessing the RV for air trapping, one should pay particular attention to the method by which lung volumes are measured. Gas-based methods for measuring lung volumes tend to underestimate the RV, especially when significant small airway obstruction is present. 47 
Diffusion capacity
The diffusion capacity, most commonly assessed by the single-breath carbon monoxide method (DL CO ), 48, 49 is a measure of the patient's ability to absorb alveolar gases into the capillary blood flow, reflecting alveolar membrane thickness, hematocrit level, cardiac output, and heterogeneity in the distribution of the diffusion capacity to regional ventilation and perfusion (in patients with pulmonary disease). 50, 51 Reduction of the diffusion capacity can be due to compromise of any or a combination of these variables, leading to a reduction of the alveolar capillary interface. Unfortunately, the DL CO is the most variable parameter in a PFT, particularly when a restrictive or obstructive ventilatory impairment is present. 52, 53 Thus, all pulmonary function laboratories should comply with the ATS recommendations for measuring the DL CO . 49 Although an adjustment of the DL CO for hemoglobin is not officially required, the changes in DL CO , as a function of hemoglobin, are well known. 54 For HCT patients, whose hemoglobin levels may vary significantly from PFT to PFT, this correction is particularly important. There are no official recommendations regarding whether the DL CO should be corrected for alveolar volume. 49 However, it is known that although a lower alveolar volume, as found in patients with pulmonary disease, may decrease the diffusion capacity, the relationship is not in a 1:1 proportion. 48, 51 In fact, several studies have demonstrated that in patients with known parenchymal lung diseases and low DL CO measurements, the alveolar volume corrected diffusion capacity often underestimated the reduction in diffusion capacity. 55, 56 Therefore, the DL CO should not be corrected for alveolar volume.
Pretransplant pulmonary function tests
Although there have been many studies that have either directly examined or included in their analysis pretrans-plant PFTs, the majority of these tests are small and descriptive. Owing to the interindividual variability of PFTs, as well as the many potential clinical variables that can have an impact upon pulmonary function, we believe the ideal study evaluating the relationship between pre-and post transplant lung function should, at minimum, be conducted on a large cohort, with adequate post transplant pulmonary function data for analysis, obtained at regular scheduled intervals. Table 3 summarizes nine studies that we believe to fit these criteria.
There have been only two small studies conducted to examine specifically the evolution of lung function after HCT. Badier et al 57 followed 117 autologous or allogeneic bone marrow transplant recipients with serial PFTs after transplant and found that patients with a history of pulmonary irradiation and toxic lung chemotherapy had lower post transplant DL CO and TLC, but other spirometric or lung volume values were not affected. Although they did not make direct comparisons with pretransplant PFTs, their analysis demonstrated that significant changes in DL CO and TLC at day 100 were generally reversed by 1 year after HCT, and were more likely to occur among patients with a history of pulmonary irradiation and toxic lung chemotherapy prior to transplant. They did not find a significant change in the FEV 1 , FVC, and FEV 1 /FVC ratio by day 100 and 1 year. Gore et al 58 found similar results, demonstrating that TLC and DL CO also significantly declined after transplant. Additionally, they also found a trend toward a correlation between the decline of FEV 1 and FVC, with the occurrence of chronic graft-versus-host disease after transplant (P ¼ 0.13). There was also a significant relationship between decreased DL CO at 2 years and the presence of chronic graft-versus-host disease (P ¼ 0.01). However, in the Badier study, they did not assess the pretransplant lung function as risk factors for post transplant PFT changes. This may be because both studies were conducted on relatively small cohorts and the authors were unable to detect significant associations between pre-and post transplant lung function abnormalities.
Many studies have been conducted to determine the risk factors for post transplant pulmonary complications, some of which have included an analysis of pretransplant pulmonary function as a potential risk factor. Ghalie et al 59 studied 160 autologous and allogeneic HCT patients for early post transplant complications. They found that the mean pretransplant FEV 1 , FVC, TLC, and DL CO were significantly lower for patients who had prior chest irradiation, thoracotomy, and/or pulmonary metastases (Pp0.01). In univariate analysis, the rate of pulmonary complications, defined as a localized or diffuse pulmonary infiltrate, pulmonary hemorrhage, and adult respiratory distress syndrome, was significantly higher in patients with reduced TLC (risk ratio (RR) 1.8, 95% confidence interval (CI) 1.2-2.6) and/or FEV 1 (RR 1.9, 95% CI 1.3-2.9) at baseline. In multivariable linear regression analysis, only the pretransplant FEV 1 was significantly associated with a higher rate of pulmonary complications (regression coefficient 0.149, P ¼ 0.0005). In a slightly smaller study, Schwarer et al 60 found no significant association between 61 In a prospective study of 307 patients, they found that a pretransplant DL CO o70% of normally predicted was associated with a significant risk for developing VOD (OR 2.4, 95% CI 1.0-5.4; P ¼ 0.04), with the incidence of severe hepatic VOD being 36.4% among patients with a pretransplant DL CO o65% of predicted, compared to an incidence of 11.9% among patients with a pretransplant DL CO 465% of predicted (P ¼ 0.001).
Studies from our group have been mainly focused on the development of AFO after HCT, which represents the most common noninfectious pulmonary complication after HCT. Clark et al 30 conducted the first large study examining clinical risk factors for developing airflow obstruction after transplant. Their analysis found the pretransplant FEV 1 /FVC ratio significantly correlated with the 1 year FEV 1 /FVC ratio (r 2 0.51, Po0.0001), suggesting that the pretransplant ratio was not significantly different from the 1 year ratio. Further unpublished analysis confirmed that a lower FEV 1 /FVC ratio obtained before transplantation was not associated with the development of AFO after transplant. We recently conducted two followup studies of our 1990-2000 allogeneic cohort to reevaluate the epidemiology of significant airflow decline and assess the implications of early airflow decline after HCT. 34, 35 In these analyses, we have consistently found a pretransplant FEV 1 /FVC ratio o0.8 to be associated with at least a doubling of the risk for the development of significant airflow decline after transplant. Unpublished analyses found similar results with pretransplant percent of predicted FEV 1 o80%. These results suggest that any evidence of AFO or lung function compromise prior to transplant may increase the risk for developing further AFO after HCT.
Additional studies have also been conducted to assess the value of the pretransplant evaluation in predicting post-HCT mortality. In 1992, Crawford conducted a study at our center that found pretransplant spirometric and lung volume measurements were not useful in predicting mortality risk during the first year after transplant. 62 However, in a multivariable model, a DL CO o80% was associated with a slightly increased risk for mortality (RR 1.43, 95% CI 1.26-1.64), as was a P(A-a)O 2 gradient 420 mmHg (RR 1.28, 95% CI 1.04-1.55). Later, Goldberg et al studied the association between pretransplant lung function and mortality within the first 100 days after HCT. In univariate analysis, pretransplant FEV 1 o78% (P ¼ 0.0002) and D LCO o52% (P ¼ 0.002) were associated with early mortality. In a multivariable analysis that included donor type, performance status, pretransplant creatinine, and bilirubin, these results were confirmed. FEV 1 and DL CO were again significantly associated with early mortality (FEV 1 : RR 4.5, P ¼ 0.0008; values for DL CO not provided).
Clinical recommendations
Since infectious and noninfectious pulmonary complications represent important complications of HCT, some of which may have lasting effects on pulmonary function, it is our recommendation that every candidate for an HCT, allogeneic or autologous, should undergo pretransplant pulmonary function testing for two main reasons. First, the pretransplant PFT provides a baseline study as a reference for future PFTs. Without a comparison pretransplant PFT, a significant decline of lung function after transplant may not be apparent. For instance, a patient with a 1 year post transplant FEV 1 of 75% may be classified as having borderline normal lung function. However, if this patient had a pretransplant FEV 1 of 98%, the 23% decrease of the FEV 1 over 1 year is very abnormal, considering the normal rate of FEV 1 decline is o1% per year. 63 Thus, only when a post transplant PFT is compared to the pretransplant lung function can it be appreciated whether significant lung function decline has occurred.
Second, pretransplant PFTs may be useful for identifying patients for whom the risk of pulmonary complications/ mortality is so high that the balance of these risks against the potential benefits of myeloablative transplantation needs to be seriously examined. The above review of the published literature investigating pretransplant lung function as a potential risk factor for post transplant pulmonary complications indicate that, despite some disagreements in regards to which PFT parameter is most useful, the overall consensus is that compromised lung function prior to transplant, whatever the degree, reflected by a lower than normal FEV 1 , TLC, or DL CO , imparts an increased risk for pulmonary complications and mortality after transplant, particularly among patients who receive a myeloablative transplant.
Future direction
A major shortcoming of our current understanding of these data is how they should be applied toward clinical management of these patients. None of the studies to date have attempted to determine and validate the predictive value of these variables in a large cohort study. For instance, how does the risk for mortality increase as pretransplant lung function worsens? Additionally, the existing data may be outdated due to recent developments in conditioning regimens. Over the last several years, nonmyeloablative HCT has become an accepted alternative for the treatment of patients considered ineligible for a myeloablative conditioning regimen, [65] [66] [67] Aside from the benefits of graft-versus tumor effect, there is now sufficient evidence to suggest that the nonmyeloablative conditioning regimen is associated with fewer pulmonary complications, such as idiopathic pneumonia syndrome. 68 Future studies examining pretransplant lung function need to be comprehensive, using large populations that include both nonmyeloablative and myeloablative conditioning regimens, to determine how pretransplant pulmonary function data can be applied clinically to assist in not only selecting a conditioning regimen, but also help project a patient's risk for significant pulmonary complications and mortality.
